About one million people living with Parkinson’s disease in the US – and 90,000 receive new diagnosis every year – the race is for a treatment.
Researchers at the Memorial Slone Catering Cancer Center (MSK) have announced progress on the front – they have developed a new therapy that uses stem cells to treat advanced Parkinson’s.
In Phase 1 Test, the researchers used stem cells (taken from the embryo of the early phase) to create nerve cells (neurons) and according to a press release by MSK, they were implanted to the minds of 12 Parkins patients.
New drug for Parkinson is shown to be effective in clinical trials: ‘very encouraged’
Once the cells are injected, they produce dopamine, a hormone in the brain that helps in movement and coordination.
(One of the identity of Parkinson’s is the low level of dopamine, which causes shock, hardness, balance issues and distinctive symptoms of difficulty walking.)
About one million people in the US are living with Parkinson’s disease, in which 90,000 get new diagnoses every year. (Istock)
Researchers reported that after 18 months, the injection cells “did not have any serious side effects in the brain.”
Based on the MDS-updrs, a rating scale-appeater-contemporary for the symptoms developed by the International Parkinson’s and Movement Disorder Society experienced “noticeable improvement”, especially the group that receives a high dose.
Patients from the high-khurak group reported 2.7 hours additional “time” each day.
“Neurologist says that things usually get slightly deteriorated every year with the disease, which means the score increases from some points,” the study co-author Lorenz Stader, Director of the Center for Stem Sale Biology, MSK, said in a press release.
“In our study, not only the score was not deteriorated, it dropped more than 20 points in the high-khurak group.”
Researchers used stem cells (taken from the embryo of the early stage) to create nerve cells (neurons) and implanted them to the brain of 12 Parkins patients. (Istock)
On average, patients with high-khurak group reported “time” in addition to 2.7 hours-indication of normal functioning with-unique symptoms-“one result that could be quite meaningful for their everyday life,” Sader said.
Given the success of step 1 testing, the US Food and Drug Administration (FDA) has approved the researchers to go directly into a very large patient group to go directly to stage 3 clinical tests – about 100 people – which will be in the first half of 2025.
The findings were published in the Nature Journal.
Parkinson’s cases can be doubled globally by 2050, studies show
“The study has shown that developing specific nerve cells from human embryo stem cells in the lab, then injecting them into the brain of people with Parkinson’s disease, is safe and promises as a potential future treatment,” the leading writer Vivian Tabar, MD, MD, Slon Catering in New York City said that Fux News Digital.
“The conclusions were rewarding, as it is more than a dozen years of creating the work.”
‘Major steps ahead’
Medical Director of MS Center at Holi Name Medical Center in Teaneck, New Jersey. Mary Ann Pickon said that cells for the treatment of Parkinson’s disease can not only provide the ability to slow down disability, but can also prevent progress and tell about improvement in motor functions.
“Although the risk involved in the required immune suppression before the stem cell implantation and the procedure is a major step to replace the lost dopaminargic neurons,” Picon, who was not involved in the study, told Fox News Digital.
Click here to get Fox News app
Levodopa, currently the first row treatment for Parkinson, is limited in the fact that patients require more doses as well as more doses according to the picon-“And either it becomes more difficult to control the duration of stiffness or dyskinesias (uncontrolled muscle activities).”
Researchers reported that after 18 months, the injection cells “did not have any serious side effects in the brain.” (Istock)
Director of Movement Disorder at WVU Rockfeller Neuroscience Institute in West Virginia. N Murray studied as “incredibly exciting” for Parkinson’s patients.
“Although the goal of this special research project was to ensure protection, but significant clinical improvement in UPDR is absolutely groundbreaking,” Murray told Fox News Digital. (She was also not involved in the study.)
Click here to sign up for our health newspaper
“This is just the first step for patients suffering from Parkinson’s disease to approve this type of medicine, but this is a wonderful first step for the possible benefits of stem cell brain therapy.”
Potential limits
There were some limitations related to the study, Tabar said.
“This is a small study designed to show safety-it is important to prove a large, well-controlled study to prove that treatment actually works, otherwise phase 3 is referred to as ‘efficacy’ studies,” he said.
“This is a wonderful first step for the possible benefits of stem cell brain therapy.”
However, these initial conclusions are “the idea of a strong promise.”
“I think we can finally say that stem cells, when obtained and separated separately, makes the brain repairing the brain in Parkinson and potentially great promises in other situations someday,” Tabar said.
For more health articles, go to www.foxnews.com/health
Cell therapy was developed in MSK and licensed for blurrock theraputics in Massachusetts, which funded the study.
